RNA splicing factors as oncoproteins and tumour suppressors.

Author Information (click to view)

Dvinge H, Kim E, Abdel-Wahab O, Bradley RK,

Dvinge H, Kim E, Abdel-Wahab O, Bradley RK, (click to view)

Dvinge H, Kim E, Abdel-Wahab O, Bradley RK,


Nature reviews. Cancer 2016 6 10() doi 10.1038/nrc.2016.51


The recent genomic characterization of cancers has revealed recurrent somatic point mutations and copy number changes affecting genes encoding RNA splicing factors. Initial studies of these ‘spliceosomal mutations’ suggest that the proteins bearing these mutations exhibit altered splice site and/or exon recognition preferences relative to their wild-type counterparts, resulting in cancer-specific mis-splicing. Such changes in the splicing machinery may create novel vulnerabilities in cancer cells that can be therapeutically exploited using compounds that can influence the splicing process. Further studies to dissect the biochemical, genomic and biological effects of spliceosomal mutations are crucial for the development of cancer therapies targeted at these mutations.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × 4 =